Simulation for the Next Era of Drug Discovery · Stellar Amenities Lab
Stellar AmenitiesLab
Menu

Simulation for the next era of drug discovery

Spaceflight compresses decades of ageing into months. A model built on that data can find drug targets faster.

What WW2 medicine taught us about the brain

Much of what neuroscience knows about how the brain divides its work came from the Second World War. Soviet neuropsychologist Alexander Luria spent the war treating soldiers with penetrating head wounds, and by matching the location of each injury to what the patient could and could not do afterward, he built a map of brain function that founded modern neuropsychology.

Many people exposed to the same extreme condition, recorded over time, reveal mechanisms that ordinary life does not show.

Spaceflight changes the body in weeks rather than decades, and every crew member who flies adds to a record that, gathered in one place, can become a model of how the body adapts.

In space, we age much faster

In NASA's Twins Study, a year in orbit changed Scott Kelly's telomeres, the activity of thousands of genes, and left radiation damage in his chromosomes. Some changes had not reversed six months after landing.

10–20 yrsof arterial ageing after six months on the ISS, measured as carotid artery stiffness.
1–1.5%of bone mass lost each month in weight-bearing bones, against about 1% a year in older adults on Earth.NASA evidence report

In orbit the body shows signs of ageing far faster than on Earth, and we still do not know why. The data comes from very few people. A model can combine every crew member's measurements and test what drives these changes.

Cells can return to a fetal-like state

When tissue heals, adult cells briefly step back into a fetal-like state and rebuild from there. A short burst of the Yamanaka factors triggers the same step without an injury, and a 2023 study in Science Advances traced both routes to prostaglandin synthesis.

Prostaglandin pathways are already familiar drug targets. Whether spaceflight, with its rapid loss and recovery of tissue, shifts this repair program is an open question that a model built on crew data could test.

Drugs and treatments that started in a model

A model does not replace a trial but it narrows millions of options to the few worth testing

Halicin

A deep learning model at MIT screened over 100 million molecules and found an antibiotic that kills resistant bacteria. Cell, 2020.

Abaucin

The same approach found a narrow-spectrum antibiotic against Acinetobacter baumannii, one of the hardest hospital infections to treat. Nature Chemical Biology, 2023.

Rentosertib

Insilico Medicine used AI to pick both the target and the molecule. It is the first drug discovered this way to report Phase 2a results. Nature Medicine, 2025.

A simulated patient population

The FDA accepted the UVA/Padova simulator of type 1 diabetes in place of animal testing for insulin dosing algorithms. A virtual patient did the work of the first experiment. J Diabetes Sci Technol, 2009.

Sources A. R. Luria, Traumatic Aphasia (1947) and The Man with a Shattered World (1972). Garrett-Bakelman et al., “The NASA Twins Study,” Science, 2019. Hughson et al., “Increased postflight carotid artery stiffness and inflight insulin resistance resulting from 6-mo spaceflight,” American Journal of Physiology, 2016. Kim et al., “Partial in vivo reprogramming enables injury-free intestinal regeneration via autonomous Ptgs1 induction,” Science Advances, 2023. “Unlocking regeneration: how partial reprogramming resembles tissue healing,” Current Opinion in Genetics & Development, 2025. Stokes et al., “A deep learning approach to antibiotic discovery,” Cell, 2020. Liu et al., “Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii,” Nature Chemical Biology, 2023. Xu et al., “A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial,” Nature Medicine, 2025. Kovatchev et al., “In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes,” Journal of Diabetes Science and Technology, 2009.
How we build it

From one experiment to the whole literature

The usual way to check a model of the body is one experiment at a time: run a study, run the same study in the model, compare. We are building the simulation the other way round. Agents gather every published spaceflight and analog result that applies, test the model against each one, and report which results the model reproduces and which it cannot.

The gaps are the useful part. Each result the model cannot explain points to a mechanism we do not yet understand, and that becomes the next experiment, on the ground or in flight.

The agents work through a shared lab notebook rather than a chat. Every assumption, run and result is written down where the team can read, audit and correct it, so the model stays something scientists can trust.

For investors

The simulation is the asset

01
A dataset no one else hasRepeated measurements of the same bodies on Earth, in analogs and in flight. Every session adds to it, and it cannot be bought or recreated quickly by a competitor.
02
A licensable modelOnce validated, the simulation is licensed to pharmaceutical companies, agencies and operators to test drugs, countermeasures and habitat designs before a trial or a flight.
03
A large market beyond spaceBone loss, muscle wasting and cardiovascular decline are the conditions of ageing on Earth. Spaceflight shows them in months, which makes the model valuable to medicine, not only to missions.
How the simulation is built: ultrasound and training data, extrapolated to the Moon and Mars.Read the technical note →